ZYBERNO
Stock Report
Updated Sep 1, 2026

MiNK Therapeutics, Inc. (INKT)

Healthcare • NASDAQ

$11.09

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
6.0/100
POOR BUSINESS
MiNK Therapeutics, Inc. (INKT) scores 6/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,112.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

MiNK Therapeutics, Inc. (INKT) stock report — Zyberno Score 6/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:11.09
Market Cap:$55.71M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$49.36M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (4)

ROA:-92.4%
Reinvestment Rate:2.0%
Fundamental Growth Rate (g):-22.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$21.45
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:47.8%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.23x
Quick Ratio:1.23x
Cash Ratio:1.16x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:1,728,025.00
Cash And Cash Equivalents:8,806,977.00
Long Term Debt:$0.00
Net Debt:-$6.35M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$11.99M

Bottom Line Performance (3)

-$11.36M
Income Before Tax:$0.00
Ebitda Ttm:-11,820,688.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:5,747,667.00
Sga Expense:6,617,247.00
Income Tax Expense:$0.00
Interest Expense:-60,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$9.62M
Current Assets:$9.30M
Ppe Net:318,474.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:23,643,538.00
Current Liabilities:7,568,743.00
Long Term Debt:$0.00
Short Term Debt:$2.45M

Equity & Capital (3)

Equity:-$14.03M
Retained Earnings:-$162.55M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,918,739.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:422,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$6.32M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:-$2.10M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:3,019,528.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:167,046.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.36
-$2.36
Earnings Per Share Ttm:-$2.26

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.18

Book Value & Capital (2)

Book Value Per Share:-$2.79
Cash Per Share:1.75

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.0%
Fundamental Growth Rate (g):-22.5%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:INKT
Company Name:MiNK Therapeutics, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:5.02M
Shares Outstanding Basic:5.02M
Shares Outstanding Diluted:5.02M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 00:48:59 UTC
Data Timestamp:2026-08-20T06:07:28.301365
Scroll to Top